Apart from AA-PET tracers, several other radiopharmaceuticals have been developed for imaging in primary and secondary brain tumors, targeting hypoxia (18F-Fluoromisonidazole, 18F-FMISO), proliferation (3’-deoxy-3 ́-[18F]-fluorothymidine, 18F-FLT), and neuroinflammation (translocator protein, TSPO). The gene discussed is TSPO; the disease is brain neoplasm.